Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cancer Cell. 2020 Apr 13;37(4):496-513. doi: 10.1016/j.ccell.2020.03.009.
Estrogen receptor-positive (ER) breast cancer is the most common breast cancer subtype. Treatment of ER breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.
雌激素受体阳性（ER）乳腺癌是最常见的乳腺癌亚型。ER 阳性乳腺癌的治疗包括抑制雌激素产生和/或直接针对 ER 的干预措施（总体上称为内分泌治疗）。虽然内分泌治疗大大降低了乳腺癌的复发和死亡率，但对这种治疗的新出现和获得性耐药仍然是一个主要挑战。已经报道了越来越多的内分泌耐药机制，包括体细胞改变、表观遗传改变和肿瘤微环境改变。在这里，我们回顾了最近在阐明内分泌治疗耐药机制方面的进展以及克服这种耐药性的潜在策略。
